This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallis, R. S.
Right arrow Articles by Ellner, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallis, R. S.
Right arrow Articles by Ellner, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2001, p. 1302-1304, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1302-1304.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Inhibition of Isoniazid-Induced Expression of Mycobacterium tuberculosis Antigen 85 in Sputum: Potential Surrogate Marker in Tuberculosis Chemotherapy Trials

Robert S. Wallis,1,* Manijeh Phillips,2 John L. Johnson,2 Luciléia Teixeira,3 Lia Márcia Massini Canedo Rocha,3 Ethel Maciel,3 Lynn Rose,4 Charles Wells,4 Moisés Palaci,3 Reynaldo Dietze,3 Kathleen Eisenach,5 and Jerrold J. Ellner1

University of Medicine and Dentistry---New Jersey Medical School, Newark, New Jersey1; Case Western Reserve University, Cleveland, Ohio2; Universidade Federal do Espírito Santo, Vitória, Brazil3; University of Arkansas for Medical Sciences, Little Rock, Arkansas5; and PathoGenesis Corporation, Seattle Washington4

Received 14 July 2000/Returned for modification 11 November 2000/Accepted 26 December 2000

Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse. In this trial, rifampin or rifalazil inhibited the induction of sputum antigen 85 by INH in a dose-dependent fashion. This approach may facilitate the evaluation of new TB drugs.

* Corresponding author. Mailing address: Department of Medicine, UMDNJ-NJMS, 185 S. Orange Ave., MSB I-503, Newark, NJ 07103-2757. Phone: (973) 972-8778. Fax: (973) 972-7790. E-mail: wallisrs{at}umdnj.edu.

Antimicrobial Agents and Chemotherapy, April 2001, p. 1302-1304, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1302-1304.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»